Table 2.
Published estimates17 used in the study population-level simulation model.
| Incidence of infection (resistant + susceptible)10,000 patient bed-days | Resistance, % | LOS, days (95%CI) | Odds ratio of mortality (95%CI) |
|---|---|---|---|
|
E. coli BSI: 3.4 (2.9, 6.3) UTI: 51.1 (49.9, 100.9) |
3GCR BSI: 7.65 (6.56, 8.75) UTI: 5.0 (4.77, 5.23) |
3GCR BSI: 2.34 (2.21, 2.48) UTI: 1.01 (0.87, 1.14) |
3GCR BSI:3.06 (1.2, 6.81) UTI: 0.52 (0.3, 0.85) |
|
K. pneumoniae BSI: 2.0 (1.7, 3.7) UTI: 13.8 (12.9, 26.8) |
3GCR BSI: 3.95 (2.92, 4.99) UTI: 4.96 (4.52, 5.4) |
3GCR BSI:7.27 (7.13,7.41) UTI:2.29 (2.1, 2.48) |
3GCR BSI: 2.23 (0.33, 8.97) UTI:0.92 (0.38, 1.89) |
|
S. aureus BSI: 5.7 (5.2, 10.9) UTI: 2.8 (2.4, 5.3) |
MRSA BSI: 14.01 (12.92, 15.11) UTI: 16.3 (14.64, 17.95) |
MRSA BSI: 7.96 (7.79, 8.13) UTI: 1.44 (1.29, 1.6) |
MRSA BSI:3.34 (1.91, 5.53) UTI: 1.43 (0.62, 2.89) |
|
P. aeruginosa BSI: 1.6 (1.3, 2.9) UTI: 20.1 (19.1, 39.2) RTI: 11.1 (10.3, 21.4) |
Ceftazidime resistant BSI: 8.07 (6.46, 9.68) UTI: 17.4 (16.54, 18.27) RTI:8.5 (8.03, 8.97) |
Ceftazidime resistant BSI: 5.04 (4.9, 5.17) UTI: 2.04 (1.87, 2.22) RTI: 1.51 (1.34, 1.67) |
Ceftazidime resistant BSI:3.86 (1.07, 11.00) UTI:1.3 (0.82, 1.97) RTI:3.03 (2.1, 4.26) |
|
E. faecium BSI: 0.6 (0.4, 1.0) UTI: 4.2 (3.7, 7.8) |
VRE BSI: 40.19 (35.45, 44.93) UTI: 44.43 (42.59, 46.27) |
VRE BSI: 2.04 (1.73, 2.34) UTI: 1.43 (1.27, 1.58) |
VRE BSI:5.01 (2.26, 10.39) UTI:1.23 (0.78, 1.84) |
BSI: Bloodstream infection; UTI: Urinary tract infection; RTI: Respiratory tract infection; 3GCR: third-generation cephalosporin resistant; VRE: vancomycin-resistant E. faecium; MRSA: methicillin-resistant Staphylococcus aureus.